Literature DB >> 33710662

Evidence for CAT gene being functionally involved in the susceptibility of COVID-19.

Yu Qian1,2, Yi Li1,2, Xinxuan Liu1,2, Na Yuan1,2, Jinjie Ma1,2, Qiwen Zheng1,2, Fan Liu1,2,3.   

Abstract

Novel coronary pneumonia (COVID-19) is a respiratory distress syndrome caused by a new type of coronavirus. Understanding the genetic basis of susceptibility and prognosis to COVID-19 is of great significance to disease prevention, molecular typing, prognosis, and treatment. However, so far, there have been only two genome-wide association studies (GWASs) on the susceptibility of COVID-19. Starting with these reported DNA variants, we found the genes regulated by these variants through cis-eQTL and cis-meQTL acting. We further did a series of bioinformatics analysis on these potential risk genes. The analysis shows that the genetic variants on EHF regulate the expression of its neighbor CAT gene via cis-eQTL. There was significant evidence that CAT and the SARS-CoV-2-related S protein binding protein ACE2 interact with each other. Intracellular localization results showed that CAT and ACE2 proteins both exists in the cell membrane and extracellular area and their interaction could have an impact on the cell invasion ability of S protein. In addition, the expression of these three genes showed a significant positive correlation in the lungs. Based on these results, we propose that CAT plays a crucial intermediary role in binding effectiveness of ACE2, thereby affecting the susceptibility to COVID-19.
© 2021 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  COVID-19; bioinformatics; candidate gene; eQTL; protein interaction

Mesh:

Substances:

Year:  2021        PMID: 33710662      PMCID: PMC8250337          DOI: 10.1096/fj.202100008

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


angiotensin‐converting enzyme 2 coronavirus disease 2019 severe acute respiratory syndrome coronavirus 2

INTRODUCTION

Novel coronary pneumonia (COVID‐19) is a respiratory distress syndrome caused by a new type of coronavirus. The disease began to break out in Wuhan, China, at the end of 2019, and officially entered the global pandemic phase in April 2020. Until now, it is still in a pandemic stage in a number of countries. , , So far, the cumulative number of deaths due to COVID‐19 worldwide has reached 1 870 000. The COVID‐19 is the direct cause of the current global political and economic turmoil. From an epidemiological perspective, an important feature of COVID‐19 is that a considerable proportion of population can turn into a state of asymptomatic or mild illness for a long time after being infected with the virus, while a small proportion quickly enter the moderate or severe stage. This phenomenon of population differences strongly suggests that the susceptibility of COVID‐19 is influenced by genetic factors. Understanding the genetic basis of susceptibility to COVID‐19 is of great significance to disease prevention, molecular typing, prognosis and treatment. However, so far, there have been only two genome‐wide association studies (GWASs) on COVID‐19. , One of them by Kachuri et al compared the genotypes of 676 individuals with positive SARS‐CoV‐2 tests and 1334 with negative tests at the genome‐wide level, and found the genetic variation on the EHF gene showing significant association with the tests results. Another GWAS by Ellinghaus et al considered 1610 severe patients as cases and 2205 mild patients or healthy people as controls, and found that genetic variants in the LZTFL1 and ABO genes were significantly associated with the severity of COVID‐19. The designs of the two studies were in fact very different in that the first one by Kachuri et al focused on the susceptibility to COVID‐19 and the second one by Ellinghaus et al focused on the prognosis of COVID‐19. Although these two studies were not very strict in the selection of control samples, the positive findings have provided an important reference for our understanding of COVID‐19 susceptibility and prognosis. As for the mechanism by which these positive locus affect the susceptibility and prognosis of COVID‐19, it is yet unclear. We next bioinformatically analyzed the potential risk genes associated with COVID‐19 susceptibility and prognosis. We found the genes regulated by these variants through cis‐eQTL and cis‐meQTL acting. We further performed protein interaction network analysis, intracellular location analysis, and gene expression correlation analysis for these potentially functionally related genes. The results showed that the genetic variants on EHF regulate the expression of its neighbor CAT gene via cis‐eQTL acting. There was significant evidence that CAT and the SARS‐CoV‐2‐related S protein binding protein interact with each other. Intracellular localization results showed that CAT protein and ACE2 both exists in the cell membrane and extracellular area. In addition, the expression of these three genes showed a significant positive correlation in the lungs. Based on these results, we propose a hypothesis that CAT plays a crucial intermediary role in binding effectiveness of ACE2, thereby affecting the susceptibility to COVID‐19.

SUPPORTIVE EVIDENCE

We started with the functional annotations of the positive findings of the two GWASs. These included the EHF rs286914 significantly associated with the susceptibility of COVID‐19 and the LZTFL1 rs11385942 and ABO rs657152 significantly associated with the prognosis of COVID‐19. Although one of the GWAS is a preprint, it also laid foundation for follow‐up research. The rs286914 is an intronic variant of EHF on chromosome 11 and the A allele of this SNP was associated with an increased risk of positive respiratory virus test (OR = 1.52, Table S1). The A allele from the 1000 genomes project showed a large frequency difference between major continents with patterns showing higher frequencies in Africa (AFR 38.20%), America (AME 33.72%), and Europe (EUR 30.82%), but lower frequencies in East Asia (EAS 12.20% ) and South Asia (SAS 15.24%, Figure 1A). Kachuri GWAS were conducted in UK Biobank participants. As a result, the genomic variants with high frequency in these populations are more likely to be detected. In this case, the variant happened to be rarer in Asians. However, this is merely a reflection of the Winner's curse. We further investigated the existing eQTL and meQTL databases, and found that rs286914 (EHF) is a cis‐eQTL of the CAT gene about 140kbp upstream and a cis‐meQTL of cg18414381 on the EHF gene in peripheral blood (Tables 1 and 2, NeQTL = 5311, NmeQTL = 4170). Rs286914 also may be the eQTL of CAT in kidney tissue (P = .08, http://mulinlab.org/qtlbase/). This insignificant result might be partially explained by an insufficient sample size (N = 166). Until now, no significant correlation between rs286914 and CAT has been observed in other tissues including the lung. In the future, the sample size needs to be expanded to further verify their correlation in other tissues, especially in lung. This finding suggested a functional role of rs286914 on the expression of CAT while it does not necessarily directly affect the expression of EHF because rs286914 is not a significant cis‐eQTL of EHF and cis‐meQTL is very common over the genome. ,
FIGURE 1

A, Global genotype frequency distribution of rs286914 in EHF; (B) Global genotype frequency distribution of rs657152 in ABO; (C): Global genotype frequency distribution of rs11385942 in LZTFL1; (D) Gene interaction networks created in GeneMania for EHF and CAT. The query genes was analyzed (striped circles) and additionally automatically generated their interacting genes (non‐striped circles). The color of the lines connecting the genes denotes the interaction types (supplementary materials). The size of the circle indicates the importance of the gene in the specific interactions while the width of lines indicates the weight of interaction between genes (Table S2). E, Correlation of CAT, ACE2, and EHF gene expression among top 6 tissues from the GTEx database (Table S6)

TABLE 1

Cis‐eQTL of SNPs associated with COVID‐19 susceptibility and prognosis in peripheral blood

SNPEACHRGeneeQTL
GeneDistance (kbp)BetaP valueFDR
rs286914A11p13 EHF CAT 140−4.781.74E‐060
rs11385942GA3p21.31 LZTFL1
rs657152A9q34.2 ABO GBGT1 100−5.005.72E‐070
TABLE 2

Cis‐meQTL of SNPs associated with COVID‐19 susceptibility and prognosis in peripheral blood

SNP EACHRGenecis‐meQTL
CpGGeneDistance (kbp)BetaseP value
rs286914 A11p13 EHF cg18414381 EHF 0.0130.0014.88E‐113
rs11385942 GA3p21.31 LZTFL1
rs657152 A9q34.2 ABO cg11879188 ABO −0.0590.0010
cg13506600 ABO −0.0350.0010
cg21160290 ABO −0.1500.0020
cg22535403 ABO −0.1170.0010
cg24267699 ABO −0.0370.0010
cg07241568 ABO −0.0100.0003.13E‐176
cg12020464 ABO 0.0310.0011.46E‐133
cg06818865 ABO −0.0190.0018.20E‐119
cg13531387 0.0190.0012.11E‐111
cg14271713 0.0080.0004.66E‐101
cg00878953 0.0070.0002.26E‐79
cg13952840 −0.0090.0012.14E‐40
cg13963044 C9orf7 190−0.0340.0032.03E‐39
cg14440550 ABO 0.0190.0014.15E‐38
cg13660174 SURF4 90−0.0100.0011.16E‐36
cg03474926 RALGDS 100−0.0040.0006.19E‐30
cg18089000 GBGT1 80−0.0070.0011.45E‐27
cg14653977 GBGT1 80−0.0090.0011.64E‐27
cg01169778 GBGT1 80−0.0050.0012.69E‐18
cg13980863 0.0030.0001.54E‐17
cg13850847 ABO −0.0060.0011.84E‐15
cg00339415 OBP2B 400.0070.0015.95E‐15
cg13040392 0.0110.0021.36E‐11
A, Global genotype frequency distribution of rs286914 in EHF; (B) Global genotype frequency distribution of rs657152 in ABO; (C): Global genotype frequency distribution of rs11385942 in LZTFL1; (D) Gene interaction networks created in GeneMania for EHF and CAT. The query genes was analyzed (striped circles) and additionally automatically generated their interacting genes (non‐striped circles). The color of the lines connecting the genes denotes the interaction types (supplementary materials). The size of the circle indicates the importance of the gene in the specific interactions while the width of lines indicates the weight of interaction between genes (Table S2). E, Correlation of CAT, ACE2, and EHF gene expression among top 6 tissues from the GTEx database (Table S6) Cis‐eQTL of SNPs associated with COVID‐19 susceptibility and prognosis in peripheral blood Cis‐meQTL of SNPs associated with COVID‐19 susceptibility and prognosis in peripheral blood We reviewed literature for evidence supporting functional links between these two genes (CAT and EHF) and respiratory diseases. CAT is downregulated in lung cancer and asthma, and promote the apoptosis of non‐small cell lung cancer cells by accelerating the degradation of caveolin‐1. At the same time, CAT had a protective effect on pulmonary fibrosis and protected lung epithelial cells from hydrogen peroxide‐induced apoptosis, supporting that CAT plays an important role in the development of respiratory system diseases. CAT also has a significant anti‐inflammatory effect that regulates the production of cytokines in white blood cells, thereby protecting alveolar cells from oxidative damage and inhibiting the replication of SARS‐CoV‐2, emphasizing its potential utility in the treatment of COVID‐19 or other severe inflammation‐related diseases in respiratory system. The observation that the EHF variant rs286914 is an eQTL of CAT, together with the lack of literature support for a functional role of EHF in lung diseases including COVID‐19, further supports our hypothesis that rs286914 on the EHF may affect COVID‐19 via regulatory effects on the expression of CAT. The GWAS study of Ellinghaus et al found that the individuals carrying the ABO rs657152 A allele showed more severe respiratory symptoms after infection (OR = 1.39, Table S1). There is no obvious difference in the frequency of rs657152 between continents (Figure 1B). In addition, we found that ABO rs657152 is a significant cis‐eQTL regulating the expression of GBGT1 in peripheral blood, located about 80 kb upstream of ABO (P = 5.72e‐7, Table 1). Meanwhile, rs657152, as a cis‐meQTL in peripheral blood, is significantly associated with the methylation level of 23 nearby methylation sites (Table 2). This region covers multiple genes (ABO, C9orf7, SURF4, RALGDS, GBGT1 and OBP2B). So far, there is no literature evidence supporting that these genes play an important role in respiratory system diseases. Besides, rs657152 was not observed as eQTL or meQTL in lung. Ellinghaus et al also found that rs11385942, located in the intron region of the LZTFL1, was significantly associated with the prognosis of COVID‐19 (OR = 2.11, Table S1). The risk allele from the 1000 genomes project showed a large frequency difference between major continents with patterns showing higher frequencies in South Asia (SAS 29.55%), but lower frequencies in Europe (EUR 8.05%), Africa (AFR 5.30%), America (AME 4.61%), and East Asia (EAS 0.5%, Figure 1C). The rs11385942 was not a significant eQTL or meQTL in the peripheral blood and lung. Given the existing literature and databases, we have not sorted out a clear chain of evidence explaining the observed genetic associations (rs657152 and rs11385942) with the prognosis of the COVD‐19. Next, we used GeneMANIA to investigate the protein‐protein interactions between EHF and CAT. This analysis identified a functional network consisting of 22 genes. Interestingly, the ACE2 gene, encoding the SARS‐CoV‐2 S protein receptor, was identified in this network having a protein level interaction with CAT (Figure 1D, Table S2). Noteworthy, among the 163 599 genes from 9 organisms, ACE2 had direct protein‐protein interactions with only 6 genes, including CAT (Figure S1, Table S3). Intracellular localization analysis , showed that CAT and ACE2 proteins both exist in the cell membrane and extracellular area which make it clear that the interaction could have an impact on the cell invasion ability of S protein (Table S5). No direct protein level interaction was found between EHF and ACE2. This result further support our hypothesis that rs286914 (EHF) as an eQTL of CAT may affect the binding efficiency of ACE2 and SARS‐CoV‐2 S protein through CAT, thereby affecting the susceptibility of COVID‐19. There is no protein‐protein interaction between the ABO and other genes where the COVID‐19 prognosis‐associated variants and methylation site are located (GBGT1, C9orf7, SURF4, RALGDS, OBP2B). As illustrated in the network diagram, several genes had the same protein domain, possibly performing same functions (Figure S2, Table S4). It remains unclear why blood type A individuals had more severe COVID‐19 prognosis than those with blood type O. We performed a correlation analysis for the expression of EHF, CAT and ACE2 based on the gene expression data of 49 tissues from the GTEx database (https://commonfund.nih.gov/GTEx/) . These 3 genes were simultaneously expressed in 40 different tissues including the lung (Table S6). In 30 different tissues including the lung, the expression levels of these 3 genes showed significant correlations for at least one pairs after Bonferroni correction (P < 4.16e‐4). The majority of these correlations were positive (80%). The most significant correlation was observed in transverse colon, where the expressions of the three genes were all strongly positively correlated (0.60 < r < 0.73, 2.37e‐63 < P < 8.47e‐38, Figure 1E). The 2th significant finding was observed in lung tissue, where the expression of the three genes all showed a significant positive correlation (0.31 < r < 0.49, 1.76e‐32 < P < 3.24e‐13), which was consistent with that observed in the transverse colon, although the correlation and significance levels were reduced. These correlation patterns indicate that there are intrinsic connections within these three genes and they may regulate the progression of lung‐related diseases together. Here, a colocalization analysis would be preferred to test whether the GWAS and eQTL signals are overlapping. However, this analysis could not be done due to the failure to obtain COVID‐19 GWAS data. When the GWAS data are available in the future, this analysis can be supplemented to verify the association between CAT and COVID‐19.

CONCLUSION

In summary, EHF rs286914 functionally regulates the expression of CAT via cis‐eQTL acting. The expressions of EHF, CAT, and ACE2 are positively correlated with each other in lung. Moreover, there was a significant protein‐protein interaction between CAT and ACE2 while no significant interactions were found between EHF and ACE2. Intracellular location analysis showed that both CAT protein and ACE2 exist in cell membrane and extracellular area and their interaction could have an impact on the cell invasion ability of S protein. These multiple lines of evidence support the hypothesis that EHF may as an intermediary to affect the binding efficiency of ACE2 to SARS‐CoV‐2 S protein through CAT, thereby affecting the susceptibility of COVID‐19.

CONFLICT OF INTEREST

The authors declare that no conflicts of interest exist.

AUTHOR CONTRIBUTIONS

Fan Liu and Yu Qian conceived the study; Yu Qian analyzed the data, prepared the figures and supporting information. All authors took part in writing the article. Fig S1 Click here for additional data file. Fig S2 Click here for additional data file. Table S1 Click here for additional data file. Table S2 Click here for additional data file. Table S3 Click here for additional data file. Table S4 Click here for additional data file. Table S5 Click here for additional data file. Table S6 Click here for additional data file. Text S1 Click here for additional data file.
  22 in total

1.  Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation.

Authors:  Sudakshina Ghosh; Allison J Janocha; Mark A Aronica; Shadi Swaidani; Suzy A A Comhair; Weiling Xu; Lemin Zheng; Suma Kaveti; Michael Kinter; Stanley L Hazen; Serpil C Erzurum
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation.

Authors:  Pimuma Rungtabnapa; Ubonthip Nimmannit; Hasseri Halim; Yon Rojanasakul; Pithi Chanvorachote
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-09       Impact factor: 4.249

3.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function.

Authors:  David Warde-Farley; Sylva L Donaldson; Ovi Comes; Khalid Zuberi; Rashad Badrawi; Pauline Chao; Max Franz; Chris Grouios; Farzana Kazi; Christian Tannus Lopes; Anson Maitland; Sara Mostafavi; Jason Montojo; Quentin Shao; George Wright; Gary D Bader; Quaid Morris
Journal:  Nucleic Acids Res       Date:  2010-07       Impact factor: 16.971

4.  The role of catalase in pulmonary fibrosis.

Authors:  Nao Odajima; Tomoko Betsuyaku; Katsura Nagai; Chinatsu Moriyama; Da-Hong Wang; Tomoko Takigawa; Keiki Ogino; Masaharu Nishimura
Journal:  Respir Res       Date:  2010-12-29

5.  High density methylation QTL analysis in human blood via next-generation sequencing of the methylated genomic DNA fraction.

Authors:  Joseph L McClay; Andrey A Shabalin; Mikhail G Dozmorov; Daniel E Adkins; Gaurav Kumar; Srilaxmi Nerella; Shaunna L Clark; Sarah E Bergen; Christina M Hultman; Patrik K E Magnusson; Patrick F Sullivan; Karolina A Aberg; Edwin J C G van den Oord
Journal:  Genome Biol       Date:  2015-12-23       Impact factor: 13.583

6.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure.

Authors:  David Ellinghaus; Frauke Degenhardt; Luis Bujanda; Maria Buti; Agustín Albillos; Pietro Invernizzi; Javier Fernández; Daniele Prati; Guido Baselli; Rosanna Asselta; Marit M Grimsrud; Chiara Milani; Fátima Aziz; Jan Kässens; Sandra May; Mareike Wendorff; Lars Wienbrandt; Florian Uellendahl-Werth; Tenghao Zheng; Xiaoli Yi; Raúl de Pablo; Adolfo G Chercoles; Adriana Palom; Alba-Estela Garcia-Fernandez; Francisco Rodriguez-Frias; Alberto Zanella; Alessandra Bandera; Alessandro Protti; Alessio Aghemo; Ana Lleo; Andrea Biondi; Andrea Caballero-Garralda; Andrea Gori; Anja Tanck; Anna Carreras Nolla; Anna Latiano; Anna Ludovica Fracanzani; Anna Peschuck; Antonio Julià; Antonio Pesenti; Antonio Voza; David Jiménez; Beatriz Mateos; Beatriz Nafria Jimenez; Carmen Quereda; Cinzia Paccapelo; Christoph Gassner; Claudio Angelini; Cristina Cea; Aurora Solier; David Pestaña; Eduardo Muñiz-Diaz; Elena Sandoval; Elvezia M Paraboschi; Enrique Navas; Félix García Sánchez; Ferruccio Ceriotti; Filippo Martinelli-Boneschi; Flora Peyvandi; Francesco Blasi; Luis Téllez; Albert Blanco-Grau; Georg Hemmrich-Stanisak; Giacomo Grasselli; Giorgio Costantino; Giulia Cardamone; Giuseppe Foti; Serena Aneli; Hayato Kurihara; Hesham ElAbd; Ilaria My; Iván Galván-Femenia; Javier Martín; Jeanette Erdmann; Jose Ferrusquía-Acosta; Koldo Garcia-Etxebarria; Laura Izquierdo-Sanchez; Laura R Bettini; Lauro Sumoy; Leonardo Terranova; Leticia Moreira; Luigi Santoro; Luigia Scudeller; Francisco Mesonero; Luisa Roade; Malte C Rühlemann; Marco Schaefer; Maria Carrabba; Mar Riveiro-Barciela; Maria E Figuera Basso; Maria G Valsecchi; María Hernandez-Tejero; Marialbert Acosta-Herrera; Mariella D'Angiò; Marina Baldini; Marina Cazzaniga; Martin Schulzky; Maurizio Cecconi; Michael Wittig; Michele Ciccarelli; Miguel Rodríguez-Gandía; Monica Bocciolone; Monica Miozzo; Nicola Montano; Nicole Braun; Nicoletta Sacchi; Nilda Martínez; Onur Özer; Orazio Palmieri; Paola Faverio; Paoletta Preatoni; Paolo Bonfanti; Paolo Omodei; Paolo Tentorio; Pedro Castro; Pedro M Rodrigues; Aaron Blandino Ortiz; Rafael de Cid; Ricard Ferrer; Roberta Gualtierotti; Rosa Nieto; Siegfried Goerg; Salvatore Badalamenti; Sara Marsal; Giuseppe Matullo; Serena Pelusi; Simonas Juzenas; Stefano Aliberti; Valter Monzani; Victor Moreno; Tanja Wesse; Tobias L Lenz; Tomas Pumarola; Valeria Rimoldi; Silvano Bosari; Wolfgang Albrecht; Wolfgang Peter; Manuel Romero-Gómez; Mauro D'Amato; Stefano Duga; Jesus M Banales; Johannes R Hov; Trine Folseraas; Luca Valenti; Andre Franke; Tom H Karlsen
Journal:  N Engl J Med       Date:  2020-06-17       Impact factor: 91.245

Review 7.  COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives.

Authors:  Jiumeng Sun; Wan-Ting He; Lifang Wang; Alexander Lai; Xiang Ji; Xiaofeng Zhai; Gairu Li; Marc A Suchard; Jin Tian; Jiyong Zhou; Michael Veit; Shuo Su
Journal:  Trends Mol Med       Date:  2020-03-21       Impact factor: 11.951

Review 8.  An overview of COVID-19.

Authors:  Yu Shi; Gang Wang; Xiao-Peng Cai; Jing-Wen Deng; Lin Zheng; Hai-Hong Zhu; Min Zheng; Bo Yang; Zhi Chen
Journal:  J Zhejiang Univ Sci B       Date:  2020-05-08       Impact factor: 3.066

9.  Pancan-meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer.

Authors:  Jing Gong; Hao Wan; Shufang Mei; Hang Ruan; Zhao Zhang; Chunjie Liu; An-Yuan Guo; Lixia Diao; Xiaoping Miao; Leng Han
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

10.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.

Authors:  Xiuyuan Ou; Yan Liu; Xiaobo Lei; Pei Li; Dan Mi; Lili Ren; Li Guo; Ruixuan Guo; Ting Chen; Jiaxin Hu; Zichun Xiang; Zhixia Mu; Xing Chen; Jieyong Chen; Keping Hu; Qi Jin; Jianwei Wang; Zhaohui Qian
Journal:  Nat Commun       Date:  2020-03-27       Impact factor: 14.919

View more
  3 in total

Review 1.  Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection.

Authors:  Juliana M Serpeloni; Quirino Alves Lima Neto; Léia Carolina Lucio; Anelisa Ramão; Jaqueline Carvalho de Oliveira; Daniela Fiori Gradia; Danielle Malheiros; Adriano Ferrasa; Rafael Marchi; David L A Figueiredo; Wilson A Silva; Enilze M S F Ribeiro; Ilce M S Cólus; Luciane R Cavalli
Journal:  Immunobiology       Date:  2021-08-17       Impact factor: 3.152

Review 2.  Evidence for CAT gene being functionally involved in the susceptibility of COVID-19.

Authors:  Yu Qian; Yi Li; Xinxuan Liu; Na Yuan; Jinjie Ma; Qiwen Zheng; Fan Liu
Journal:  FASEB J       Date:  2021-04       Impact factor: 5.191

Review 3.  Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review.

Authors:  Evangelia Eirini Tsermpini; Una Glamočlija; Fulden Ulucan-Karnak; Sara Redenšek Trampuž; Vita Dolžan
Journal:  Antioxidants (Basel)       Date:  2022-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.